vTv Therapeutics (VTVT) Total Current Liabilities (2014 - 2026)

vTv Therapeutics has disclosed Total Current Liabilities across 13 years of filings, most recently posting $6.9 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $6.9 million, up 59.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.9 million (up 59.43% YoY), and the FY2025 annual result was $6.6 million, up 27.81% from the prior year.
• Total Current Liabilities came in at $6.9 million for Q1 2026 at vTv Therapeutics, up from $6.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $12.7 million in Q1 2022 to a low of $4.3 million in Q1 2025.
• The 5-year median for Total Current Liabilities is $7.7 million (2022), against an average of $8.1 million.
• Across the five-year window, Total Current Liabilities soared 146.03% in 2022 and tumbled 51.62% in 2025, its largest moves.
• vTv Therapeutics' Total Current Liabilities stood at $7.7 million in 2022, then jumped by 37.77% to $10.6 million in 2023, then plunged by 51.07% to $5.2 million in 2024, then gained by 27.81% to $6.6 million in 2025, then rose by 3.61% to $6.9 million in 2026.
• The last three Total Current Liabilities figures came in at $6.9 million (Q1 2026), $6.6 million (Q4 2025), and $10.2 million (Q3 2025), per Business Quant data.